MTOR and renal cell carcinoma: The pivotal phase III trial, the METEOR study, has evaluated cabozantinib (at dose of 60 mg once daily) versus everolimus an mTOR inhibitor (at dose of 10 mg daily) in advanced RCC 658 patients with progressive disease after VEGFR TKIs [30].